WallachBeth Capital Completes $4.2 Million Public Offering for Tenon Medical, Inc.
WallachBeth Capital Completes $4.2 Million Public Offering for Tenon Medical, Inc.
In a significant advancement for the medical device sector, WallachBeth Capital LLC has announced the successful closing of Tenon Medical, Inc.'s public offering, raising $4.2 million. This offering positions Tenon Medical to enhance its offerings and reach within the healthcare community, particularly for patients with sacro-pelvic disorders.
Offering Details
The public offering comprised 11,052,631 shares of common stock with a par value of $0.001 per share, along with common stock purchase warrants that allow the purchase of up to an additional 13,263,159 shares. The combined public offering price was set at $0.38 per share, including the exercise price of pre-funded warrants. Should Tenon Medical opt for a reverse stock split, the shares underlying the warrants could increase to 16,578,949.
The proceeds from this offering will play a crucial role in alleviating existing convertible notes, expanding the company’s product portfolio, and financing various marketing and sales activities. This expansion includes ensuring that clinicians are well-trained on current procedures, increasing direct sales representatives, and broadening external distribution networks.
Utilization of Proceeds
Tenon Medical plans to apply the raised funds towards several strategic initiatives. These include:
- - Partial Redemption of Convertible Notes: Addressing outstanding financial obligations to bolster fiscal health.
- - Product Portfolio Expansion: Investing in the training of healthcare providers and clinicians to ensure they can effectively utilize Tenon’s innovative solutions.
- - Hiring Sales Representatives: Strengthening the sales team to enhance outreach and generate better sales figures.
- - Clinical Research Support: Funding ongoing clinical studies to elevate reimbursement and coverage efforts, proving the efficacy of Tenon’s medical solutions.
- - Research and Development: Allocating funds to develop new products, which includes preparations for future launches, ensuring Tenon remains at the cutting edge of medical device technology.
- - Inventory and Instrumentation: Increasing necessary capacities to meet projected demands in both current and future undertakings.
- - General Corporate Purposes: Fulfilling general operational needs that support the company’s overarching goals.
Regulatory Framework and Filing
The securities are issued under a registration statement filed and effective with the Securities and Exchange Commission (SEC). Interested investors can reference the corresponding preliminary prospectus and final prospectus to gain insights into the details of the offering.
WalletBeth Capital LLC served as the sole placement agent and has extensive experience in facilitating capital market transactions for healthcare entities, assisting them in connecting with top-tier institutions. Legal support was provided by Sichenzia Ross Ference Carmel LLP for the company and Sheppard, Mullin, Richter & Hampton LLP for WallachBeth Capital LLC, ensuring compliance throughout the transaction.
Conclusion
The successful closing of this public offering is a promising step for Tenon Medical, reflecting their commitment to transforming care for patients facing sacro-pelvic disorders. WallachBeth Capital continues to support the growth and development of medical companies, driving innovation while addressing critical healthcare needs.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.